All In Biotech

Drugs by condition

Drugs approved for small cell lung cancer

Brand-name prescription drugs and biologics whose FDA label lists small cell lung cancer as an approved use. Matched on the label phrases: "small cell lung cancer".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

84

Still marketed, NDA or BLA

Drug classes

12

Novel drugs

47

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for small cell lung cancer.

  • Jideytro (Zidesamtinib) · Nuvalent NovelOrphanJul 22, 2026
  • Avopef (Etoposide) · Avyxa Holdings Feb 13, 2026
  • Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj) · Janssen Biotech Priority reviewDec 17, 2025
  • Hyrnuo (Sevabertinib) · Bayer Healthcare NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 19, 2025
  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025

All approved drugs for small cell lung cancer, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 68 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Kinase Inhibitor (14)

  • Hernexeos Zongertinib · Boehringer Ingelheim · 2025
  • Lazcluze Lazertinib Mesylate · Janssen Biotech · 2024
  • Augtyro Repotrectinib · Bristol · 2023
  • Gavreto Pralsetinib · Rigel Pharms · 2020
  • Retevmo Selpercatinib · Eli Lilly and CO · 2020
  • Lorbrena Lorlatinib · Pfizer · 2018
  • Alunbrig Brigatinib · Takeda Pharms USA · 2017
  • Tagrisso Osimertinib Mesylate · Astrazeneca · 2015
  • Gilotrif Afatinib Dimaleate · Boehringer Ingelheim · 2013
  • Xalkori Crizotinib · Pf Prism Cv · 2011
  • Retevmo Selpercatinib · Eli Lilly and CO · 2024
  • Xalkori Crizotinib · Pf Prism Cv · 2023
  • Zykadia Ceritinib · Novartis · 2019
  • Iressa Gefitinib · Astrazeneca · 2015

Vascular Endothelial Growth Factor Inhibitor (6)

  • Avastin Bevacizumab · Genentech · 2004
  • Jobevne Bevacizumab-Nwgd · Biocon Biologics INC · 2025
  • Vegzelma Bevacizumab-Adcd · Celltrion · 2022
  • Alymsys Bevacizumab-Maly · Amneal Pharms LLC · 2022
  • Zirabev Bevacizumab-Bvzr · Pfizer INC · 2019
  • Mvasi Bevacizumab-Awwb · Amgen INC · 2017

Microtubule Inhibitor (6)

Programmed Death Receptor-1 Blocking Antibody (4)

  • Tecentriq Atezolizumab · Genentech INC · 2016
  • Opdivo Nivolumab · Bristol Myers Squibb · 2014
  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
  • Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024

Endoglycosidase (3)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
  • Rybrevant Faspro Amivantamab and Hyaluronidase-Lpuj · Janssen Biotech · 2025
  • Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024

CTLA-4-directed Blocking Antibody (2)

  • Imjudo Tremelimumab-Actl · Astrazeneca Ab · 2022
  • Yervoy Ipilimumab · Bristol Myers Squibb · 2011

Topoisomerase Inhibitor (2)

  • Avopef Etoposide · Avyxa Holdings · 2026
  • Vepesid Etoposide · Onesource Specialty · 1986

Alkylating Drug (1)

Programmed Death Ligand-1 Blocker (1)

  • Imfinzi Durvalumab · Astrazeneca Uk LTD · 2017

Vascular Endothelial Growth Factor Receptor 2 Antagonist (1)

  • Cyramza Ramucirumab · Eli Lilly and CO · 2014

Folate Analog Metabolic Inhibitor (1)

  • Axtle Pemetrexed Dipotassium · Avyxa Holdings · 2024

Class not listed in FDA's data (43)

  • Jideytro Zidesamtinib · Nuvalent · 2026
  • Hyrnuo Sevabertinib · Bayer Healthcare · 2025
  • Zegfrovy Sunvozertinib · Dizal · 2025
  • Ibtrozi Taletrectinib Adipate · Nuvation · 2025
  • Emrelis Telisotuzumab Vedotin-Tllv · Abbvie INC · 2025
  • Datroway Datopotamab Deruxtecan-Dlnk · Daiichi Sankyo INC · 2025
  • Ensacove Ensartinib Hydrochloride · Xcovery · 2024
  • Bizengri Zenocutuzumab-Zbco · Merus N.V. · 2024
  • Imdelltra Tarlatamab-Dlle · Amgen INC · 2024
  • Krazati Adagrasib · Bristol · 2022
  • Lumakras Sotorasib · Amgen INC · 2021
  • Rybrevant Amivantamab-Vmjw · Janssen Biotech · 2021
  • Cosela Trilaciclib Dihydrochloride · Pharmacosmos · 2021
  • Tepmetko Tepotinib Hydrochloride · Emd Serono INC · 2021
  • Tabrecta Capmatinib Hydrochloride · Novartis Pharm · 2020
  • Enhertu Fam-Trastuzumab Deruxtecan-Nxki · Daiichi Sankyo · 2019
  • Rozlytrek Entrectinib · Genentech INC · 2019
  • Libtayo Cemiplimab-Rwlc · Regeneron Pharmaceuticals · 2018
  • Braftovi Encorafenib · Array Biopharma INC · 2018
  • Mektovi Binimetinib · Array Biopharma INC · 2018
  • Alecensa Alectinib Hydrochloride · Hoffmann-La Roche · 2015
  • Tafinlar Dabrafenib Mesylate · Novartis · 2013
  • Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
  • Alimta Pemetrexed Disodium · Lilly · 2004
  • Hycamtin Topotecan Hydrochloride · Sandoz · 1996
  • Taxotere Docetaxel · Sanofi Aventis US · 1996
  • Photofrin Porfimer Sodium · Pinnacle Biolgs · 1995
  • Avgemsi Gemcitabine Hydrochloride · Avyxa Holdings · 2025
  • Rozlytrek Entrectinib · Genentech INC · 2023
  • Pemetrexed Pemetrexed Disodium · Shilpa · 2023
  • Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
  • Tafinlar Dabrafenib Mesylate · Novartis · 2023
  • Docetaxel Docetaxel · Avyxa Holdings · 2022
  • Pemetrexed Disodium Pemetrexed Disodium · Hospira · 2022
  • Pemetrexed Disodium Pemetrexed Disodium · Sandoz · 2022
  • Pemetrexed Pemetrexed · Actavis · 2020
  • Pemfexy Pemetrexed · Eagle Pharms · 2020
  • Docetaxel Docetaxel · Actavis · 2013
  • Gemcitabine Hydrochloride Gemcitabine Hydrochloride · Hospira INC · 2011
  • Docetaxel Docetaxel · Sandoz · 2011
  • Topotecan Hydrochloride Topotecan Hydrochloride · Hospira INC · 2011
  • Hycamtin Topotecan Hydrochloride · Sandoz · 2007
  • Etopophos Preservative Free Etoposide Phosphate · Cheplapharm · 1996

Drugs in development for small cell lung cancer

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • PF-08634404SSGJ-707Phase 312 trials

    Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)

  • ZimberelimabAB122, GS-0122Phase 312 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

2 discontinued brand-name drugs whose label still names it

More on small cell lung cancer: recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.